PMCB - Dinamika pendapatan YoY sajrone rolas wulan kepungkur pharmacyte.com

Tandha merek PharmaCyte Biotech, Inc. (PMCB)

Year-over-year revenue dynamics for the trailing twelve months (TTM) demonstrate the current status of PharmaCyte Biotech (PMCB), where the figure remains at 0.00. PharmaCyte Biotech is developing the Cell-in-a-Box platform for live cell delivery in tumor therapy, ensuring pricing power. The company plans to generate revenue through cell encapsulation for the treatment of solid neoplasms. A unique patent creates a defensive barrier, although prolonged testing is slowing capitalization growth.

PMCB: Wutah dodolan YoY (TTM) PharmaCyte Biotech 11.02.2024 - 15.11.2026

Ringkesan rincian data analitis PharmaCyte Biotech (PMCB)

- kuotasi saiki lan rata-rata prakiraan nilai:
Kutipan saham PharmaCyte|PMCB - Prakiraan konsensus analis
- statistik kapitalisasi pasar:
Nilai pasar PharmaCyte Biotech Inc.|PMCB - Nilai Total Perusahaan
- informasi kapitalisasi buku:
Nilai Buku Saham PharmaCyte Biotech|PMCB - Kapitalisasi Buku|Nilai Pasar marang Nilai Buku pharmacyte.com|PMCB - Total Aset Perusahaan
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal PharmaCyte Biotech|PMCB - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal PharmaCyte Biotech|PMCB - Utang perusahaan|Utang marang nilai buku PharmaCyte Biotech, Inc.|PMCB - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan PharmaCyte Biotech|Indikator likuiditas cepet pharmacyte.com
- informasi bathi lan kelipatan valuasi:
PMCB - Penghasilan resik|Bathi resik sing dikarepake PharmaCyte Biotech|PMCB - Koefisien rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep PharmaCyte|PMCB - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan PharmaCyte|PMCB - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku PharmaCyte Biotech|PMCB - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan pharmacyte.com|PMCB - Wutah bathi ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep PharmaCyte Biotech
- indikator pendapatan dodolan lan penghasilan bisnis:
PMCB - Pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan pharmacyte.com|PMCB - Kapitalisasi marang pendapatan|Rasio rega marang pendapatan sing dikarepake PharmaCyte Biotech, Inc.|PMCB - Wutah dodolan YoY (TTM)
Analisis kabeh metrik perusahaan:PMCB - pharmacyte.com
Produk asli PharmaCyte

Amidst the strategic pivot of PharmaCyte Biotech (PMCB) and the freezing of early R&D tests to preserve liquidity, traditional revenue is taking a backseat. This metric measures the percentage change in sales volumes over a rolling year to smooth out quarterly fluctuations; analyzing this rolling 12-month sales volume chart against YoY figures allows investors to assess the actual resilience of the business model while the company seeks pharmaceutical partners.

Karo sapa PharmaCyte Biotech saingan

TLSI - Wutah pendapatan YoY sajrone 12 wulan kepungkur|RenovoRx, Inc. - Wutah dodolan YoY (TTM)